Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sujai Nath

Neurology Boca Raton, FL Medical Doctor

NPI 1255337382 CMS profile 683957

800 Meadows Rd, Boca Raton, FL 33486

Open in the dashboard

General payments

$3,756

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sujai Nath of Boca Raton, FL is reported in the CMS Open Payments database as having received $3,756 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $794 28
2024 General $938 20
2023 General $191 3
2021 General $274 3
2019 General $1,559 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sujai Nath
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sujai Nath were reported at $794. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sujai Nath Neurology median Middle half National median
2019 $1,559 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $274 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $191 $464 $119–$2,312 $160
2024 $938 $468 $119–$2,323 $164
2025 $794 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $1,324 16 payments
  2. Alexion Pharmaceuticals, Inc. $330 7 payments
  3. Janssen Pharmaceuticals, Inc $287 4 payments
  4. Medtronic, Inc. $274 2 payments
  5. Novo Nordisk Inc $263 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $161 5 payments
  7. AbbVie, Inc. $159 4 payments
  8. UCB, Inc. $147 6 payments
  9. Teva Pharmaceuticals USA, Inc. $133 2 payments
  10. CSL Behring $121 4 payments
  11. Other $557 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,796 68 payments
  2. Travel and Lodging $711 3 payments
  3. Honoraria $150 1 payment
  4. Education $100 3 payments
Products named General payments · program years 2019–2025
  1. LIORESAL $1,121 8 payments
  2. XARELTO $326 5 payments
  3. LINQ II $274 2 payments
  4. Wegovy $263 3 payments
  5. SYNCHROMED $203 8 payments
  6. Soliris $183 3 payments
  7. HYQVIA $161 5 payments
  8. UBRELVY $159 4 payments
  9. Austedo XR $133 2 payments
  10. APTIOM $103 1 payment
  11. Other $799 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$52,293

Medicare's payments for the services billed

Medicare patients

408

Average age 79

Services billed

827

209 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 55%
Atrial fibrillation 50%
Depression 47%
Chronic kidney disease 43%
Diabetes 39%
Alzheimer's or dementia 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $155
  • Janssen Scientific Affairs, LLC $40
$195 — —
Wegovy
  • Novo Nordisk Inc $138
$138 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $120
$120 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $69
$69 — —
Kcentra
  • CSL Behring $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record